This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beckman, J. A. Articles by Creager, M. A. Search for Related Content PubMed PubMed Citation Articles by Beckman, J. A. Articles by Creager, M. A. Related Collections Peripheral vascular disease AHA Statements and Guidelines Other diagnostic testing

(Circulation. 2006;114:861-866.)
© 2006 American Heart Association, Inc.

Special Report

The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease

More Harm Than Benefit?

Joshua A. Beckman, MD, MS; Michael R. Jaff, DO; Mark A. Creager, MD

From the Cardiovascular Division (J.A.B., M.A.C.), Brigham and Women’s Hospital, Boston, Mass; and the Division of Cardiovascular Medicine (M.R.J.), Massachusetts General Hospital, Boston, Mass.

Correspondence to Joshua A. Beckman, MD, Cardiovascular Division, 75 Francis St, Boston, MA 02115. E-mail jbeckman{at}partners.org

Under the auspices of the Agency for Healthcare Research and Quality, the United States Preventive Services Task Force (USPSTF) recently released an update to its 1996 Peripheral Arterial Disease (PAD) Screening Recommendation Statement. The USPSTF recommended against PAD screening, giving the practice a "D" level recommendation. This level suggests that little or no benefit could accrue from PAD screening and that screening-associated harm could occur. The present commentary disputes the Task Force’s recommendation. The USPSTF statement omitted important peer-reviewed data on the prevalence, screening efficacy, and short-term adverse prognosis of patients with PAD and failed to consider the beneficial outcomes that probably would result from timely diagnosis and treatment of this important manifestation of atherosclerosis. The Task Force implied that screening may lead to unnecessary tests, including increased risk associated with use of contrast angiographic studies. However, most patients with PAD have neither classic symptoms of leg claudication nor threatened limbs but have an extraordinarily high rate of adverse cardiovascular events, such as myocardial infarction, stroke, and death—events that should serve as a key rationale for screening. Medical therapy, including risk factor modification and antiplatelet medications, is known to reduce cardiovascular morbidity and mortality rates in these patients. The Task Force’s recommendation against PAD detection may itself adversely result in inadequate recognition and treatment of PAD, with adverse public health consequences. We encourage the USPSTF to reevaluate the extant data, add vascular specialty expertise to its review group, and reconsider its recommendation.

Key Words: peripheral vascular disease • diagnosis • tests • mortality • atherosclerosis

This article has been cited by other articles:

				T. S. Perlstein and M. A. Creager The Ankle-Brachial Index as a Biomarker of Cardiovascular Risk: It's Not Just About the Legs Circulation, November 24, 2009; 120(21): 2033 - 2035. [Full Text] [PDF]

				E. T Fung, A. M Wilson, F. Zhang, N. Harris, K. A Edwards, J. W Olin, and J. P Cooke A biomarker panel for peripheral arterial disease Vascular Medicine, August 1, 2008; 13(3): 217 - 224. [Abstract] [PDF]

				R. Migliacci, R. Nasorri, P. Ricciarini, and P. Gresele Ankle-brachial index measured by palpation for the diagnosis of peripheral arterial disease Fam. Pract., August 1, 2008; 25(4): 228 - 232. [Abstract] [Full Text] [PDF]

				S. Stern Are We Getting Nearer to Screening for Atherosclerosis? Circulation, January 1, 2008; 117(1): 122 - 126. [Full Text] [PDF]

				S. Haugen, I. P. Casserly, J. G. Regensteiner, and W. R. Hiatt Risk assessment in the patient with established peripheral arterial disease Vascular Medicine, November 1, 2007; 12(4): 343 - 350. [Abstract] [PDF]

				S. Dalager, W. P. Paaske, I. Bayer Kristensen, J. Marsvin Laurberg, and E. Falk Artery-Related Differences in Atherosclerosis Expression: Implications for Atherogenesis and Dynamics in Intima-Media Thickness Stroke, October 1, 2007; 38(10): 2698 - 2705. [Abstract] [Full Text] [PDF]

				B. H. Annex Is a Simple Biomarker for Peripheral Arterial Disease on the Horizon? Circulation, September 18, 2007; 116(12): 1346 - 1348. [Full Text] [PDF]

				A. M. Wilson, E. Kimura, R. K. Harada, N. Nair, B. Narasimhan, X.-Y. Meng, F. Zhang, K. R. Beck, J. W. Olin, E. T. Fung, et al. {beta}2-Microglobulin as a Biomarker in Peripheral Arterial Disease: Proteomic Profiling and Clinical Studies Circulation, September 18, 2007; 116(12): 1396 - 1403. [Abstract] [Full Text] [PDF]

				J. P Cooke SVMB Presidential address: Vascular medicine: past, present and future Vascular Medicine, August 1, 2007; 12(3): 215 - 218. [PDF]

				T. W. Rooke Controversies in vascular screening art versus science Vascular Medicine, August 1, 2007; 12(3): 235 - 242. [Abstract] [PDF]

				N. Calonge and D. Petitti Letter by Calonge and Petitti Regarding Article, "The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease: More Harm Than Benefit?" Circulation, February 27, 2007; 115(8): e212 - e212. [Full Text] [PDF]

				J. A. Beckman, M. A. Creager, and M. R. Jaff Response to Letter Regarding Article, "The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease: More Harm Than Benefit?" Circulation, February 27, 2007; 115(8): e213 - e213. [Full Text] [PDF]

				J. A. Beckman Peripheral Endovascular Revascularization: Some Proof in the Pudding? Circulation, February 6, 2007; 115(5): 550 - 552. [Full Text] [PDF]